Talimogene Laherparepvec Plus Pembrolizumab for Advanced Melanoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma
J. Clin. Oncol 2022 Aug 23;[EPub Ahead of Print], JA Chesney, A Ribas, GV Long, JM Kirkwood, R Dummer, I Puzanov, C Hoeller, TF Gajewski, R Gutzmer, P Rutkowski, L Demidov, P Arenberger, SJ Shin, PF Ferrucci, A Haydon, J Hyngstrom, JV van Thienen, S Haferkamp, JM Guilera, BL Rapoport, A VanderWalde, SJ Diede, JR Anderson, S Treichel, EL Chan, S Bhatta, J Gansert, FS Hodi, H GogasFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.